GENETIC TEST:
Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics

FULL NAME:	Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics
DESCRIPTION:	5-fluorouracil (5-FU) toxicity -Dihydropyrimidine dehydrogenase deficiency - DPYD genotyping - Pharmacogenetics
TEST TYPE:	Clinical
TEST SPECIALTY:	Molecular Genetics
TEST PURPOSE:	Therapeutic Management
SPECIMEN:	Peripheral (whole) blood on EDTA
METHOD CATEGORY:	Targeted variant analysis
METHOD TECHNIQUE:	Bi-directional Sanger Sequence analysis
RIZIV CODE:	565390-565401
EQA:	• Dihydropyrimidine dehydrogenase deficiency

TURNAROUND TIME (MAXIMUM):	2 weeks
CREATED:	20 Dec 2019 - 14:40
CHANGED:	24 Jan 2023 - 13:55
URL:	https://www.cmgg.be/nl/zorgverlener/labguide/constitutioneel-genetische-aandoen…

RELATED CONTENT

Related Diseases

- Dihydropyrimidine dehydrogenase deficiency

Related Laboratories

- Centrum Medische Genetica - UZ Gent

Related Analytes

- dihydropyrimidine dehydrogenase